• 제목/요약/키워드: Interleukin-17

검색결과 233건 처리시간 0.034초

Insulin Resistance and Serum Levels of Interleukin-17 and Interleukin-18 in Normal Pregnancy

  • Jahromi, Abdolreza Sotoodeh;Shojaei, Mohammad;Ghobadifar, Mohamed Amin
    • IMMUNE NETWORK
    • /
    • 제14권3호
    • /
    • pp.149-155
    • /
    • 2014
  • We performed this study to evaluate the role of Interleukin-17 (IL-17) and Interleukin-18 (IL-18) in insulin resistance during normal pregnancy. This descriptive cross sectional study was carried out on 97 healthy pregnant women including 32, 25, and 40 individuals in the first, second, and third trimesters, respectively, and on 28 healthy non pregnant women between the autumn of 2012 and the spring of 2013. We analyzed the serum concentrations of IL-17 and IL-18 by using the enzyme linked immunosorbent assay (ELISA). Insulin resistance was measured by homeostasis model assessment of insulin resistance equation. No significant differences between the demographic data of the pregnant and non pregnant groups were observed. Insulin resistant in pregnant women was significantly higher than the controls (p=0.006). Serum IL-17 concentration was significantly different in non pregnant women and pregnant women in all gestational ages (p<0.05). Serum IL-18 level was significantly lower in subjects with first, second, and third trimesters of pregnancy in compared to non pregnant women (p<0.05). No significant correlations were found between serum IL-17 and IL-18 levels with insulin resistance (r=0.08, p=0.34 vs. r=0.01, p=0.91, respectively). Our data suggested that IL-17 and IL-18 do not appear to attribute greatly to pregnancy deduced insulin resistance during normal pregnancy.

($17{\beta}$-Estradiol 및 1,25-Dihydroxyvitamin $D_3$가 치주인대 세포의 Interleukin-6의 생성에 미치는 영향 (Effect of $17{\beta}$-Estradiol and 1,25-Dihydroxyvitamin $D_3$ on Interleukin-6 Production of Periodontal Ligament Cells)

  • 곽월아;최봉규;이현정;유윤정
    • Journal of Periodontal and Implant Science
    • /
    • 제29권3호
    • /
    • pp.645-654
    • /
    • 1999
  • Interleukin-6(IL-6) stimulate osteoclast differentiation. $17{\beta}$-estradiol, 1,25-dihydroxyvitamin $D_3$(1,25-$(OH)_2D_3$) and interleukin-$1{\beta}$ inhibit or stimulate osteoclast differentiation by decreasing or increasing the synthesis of interleukin-6(IL-6) from stromal/osteoblastic cells, respectively. Periodontal ligament(PDL) cells reside between the alveolar bone and the cementum and have osteoblastic characteristics. To estimate the effect of $17{\beta}$-estradiol and 1,25$(OH)_2D_3$ on IL-6 production of PDL cells, PDL cells were treated with $17{\beta}$-estradiol or 1,25-$(OH)_2D_3$ in the absence or the presence of IL-$1{\beta}$. The concentration of IL-6 produced form PDL cells was determined by enzym linked immunosorbent assay(ELISA). In unstimulated PDL cells, we detected constitutive production of IL-6 at 1st and 2nd day. IL-$1{\beta}$ increased IL-6 synthesis at 1st day and 2nd day. $17{\beta}$-estradiol had no significant effect on the secretion of this cytokine, either constitutively or after stimulation with IL- $1{\beta}$(0.05 ng/ml). 1,25-$(OH)_2D_3$($10^{-8}M$) decreased not only constitutive IL-6 production but also IL-$1{\beta}$-induced IL-6 production at 2nd day. These results suggest that 1,25-$(OH)_2D_3$ may control IL-$1{\beta}$-induced osteoclast differentiation by decreasing IL-$1{\beta}$-induced IL-6 secretion of PDL cells.

  • PDF

Interleukin-17의 발현이 염증성장질환의 발생과 진행에 끼치는 영향 (Interleukin-17 in the Inflammatory Bowel Disease)

  • 이초롱;박성규
    • 한양메디칼리뷰
    • /
    • 제33권1호
    • /
    • pp.27-32
    • /
    • 2013
  • Inflammatory bowel diseases(IBD), including Crohn's disease and ulcerative colitis, are chronic inflammatory states of the intestinal tract. While the exact mechanisms inducing chronic inflammation are still unclear, it is hypothesized that the inflammation is caused in part by an inappropriate immune response to the intestinal microflora. Although inflammatory diseases are not directly linked to patient survival, symptoms of these diseases significantly decrease quality of life. The incidence rate is higher in western people than eastern people, but the incidence rate of IBD in eastern people, including Korean, is increasing. Recently, it has been reported that IL-17 is an important factor that appears to be involved in IBD induction and progression. This report reviews many recent papers reporting the relationship between IBD and IL-17, which may provide an understanding leading to new means of prevention and treatment for IBD.

Reduced Interleukin-17 and Transforming Growth Factor Beta Levels in Peripheral Blood as Indicators for Following the Course of Bladder Cancer

  • Baharlou, Rasoul;Vasmehjani, Abbas Ahmadi;Dehghani, Ali;Ghobadifar, Mohamed Amin;Khoubyari, Mahshid
    • IMMUNE NETWORK
    • /
    • 제14권3호
    • /
    • pp.156-163
    • /
    • 2014
  • Interleukin (IL) 17 is produced by T-helper (Th) 17 with a vigorous effect on cells of the immune system playing important roles in pathogenesis of immune-mediated diseases, including autoimmune disorders and cancers. Therefore, the aim of current study was to determine the serum levels of IL-6, IL-17, and transforming growth factor beta (TGF-${\beta}$) in Iranian bladder cancer patients, and to correlate them with disease status. Blood samples were collected from 40 bladder cancer patients and 38 healthy individuals with no history of malignancies or autoimmune disorders. The serum levels of IL-6, IL-17, and TGF-${\beta}$ were measured by the enzyme-linked immunosorbent assay (ELISA). The results showed that the levels of IL-17 (p<0.0001) and TGF-${\beta}$ (p<0.0001) were significantly lower in the patients compared to the controls. No significant differences in the level of serum IL-6 (p=0.16) was observed between the patients and controls. In addition, demographic characteristics between control and patients groups were not significantly different. As most of the cases studied in this investigation were in stage I and II, it is concluded that reduced Th17-related cytokines can be used as indicators for following the course and clinical stages of bladder carcinoma progress and immune response to cancer.

Association between Polymorphisms of Interleukin-17A and Interleukin-17F Genes and Silicosis Susceptibility in Chinese Han People

  • Chen, Ying;Fan, Xue-Yun;Jin, Yu-Lan;Yao, San-Qiao;Yun, Xiang;Hua, Zheng-Bing;Shen, Fu-Hai
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권20호
    • /
    • pp.8775-8778
    • /
    • 2014
  • Background: To explore the relationship between polymorphisms of interleukin17 (IL-17) gene(A-832G 7488A/G) and the susceptibility to silicosis, a risk factor for lung cancer. Materials and Methods: A total of 113 silicosis patients and 116 workers without silicosis were enrolled in the case-control study. IL-17A A-832G and IL-17F 7488A/G polymorphisms were evaluated by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results: The frequencies of AA,GG and AG of IL-17A A-832G locus in the case and control groups were 46.9%, 8.0%, 45.1%, and 49.2%, 7.6%, 43.2%, respectively, with no significant differences (p>0.05).The GG genotype in the IL-17F (7488A/G) locus was not found. The frequencies of AA and GA of IL-17F 7488A/G locus in the case and control groups were 84.1%, 15.9% and 66.4%, 33.6%, respectively (p<0.05). Analysis of combined effects showed that the individuals with GG+AG genotype of IL-17A and GG+GA genotype of IL-17F are protected against silicosis (OR=0.469). Conclusions: IL-17F 7488A/G is associated with susceptibility to silicosis, and G allele may have a protective effect. No relationship was found between IL-17A gene polymorphisms at A-832G and silicosis.

Meta-analysis of Associations between Interleukin-17 Gene Polymorphisms and Risk of Gastric Cancer

  • Yu, Hui;Sun, Si;Liu, Fang;Xu, Qing-Hua
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제15권20호
    • /
    • pp.8709-8713
    • /
    • 2014
  • Background: Previous studies have indicated that single nucleotide polymorphisms (SNPs) of the interleukin-17 (IL-17) gene are associated with an increased risk of gastric cancer. However, the findings were inconsistent. Materials and Methods: To provide a more reliable estimation of the association between SNPs in the IL-17 gene and the susceptibility to gastric cancer, we searched PubMed, CNKI, and Wan Fang databases and selected finally six studies covering 2,366 cases and 3,205 controls to perform a meta-analysis. Results: Statistical analyses showed that an rs2275913 polymorphism within the IL-17A gene was significantly associated with an increased risk of gastric cancer using a generalized odds ratio (ORG, a model-free approach). Moreover, we also found that the 'A' allele carriers of IL-17A rs2275913 had a significant link with clinicopathological features. However, no significant positive signals were observed in the association analysis of the rs3748067 and rs763780 polymorphisms with the risk of gastric cancer in IL-17A and IL-17F, respectively. Conclusions: Despite some limitations, the present meta-analysis provided a more precise estimation of the relationship between the IL-17 gene SNPs and gastric cancer risk compared with individual studies.

IL-17 and IL-21: Their Immunobiology and Therapeutic Potentials

  • Choong-Hyun Koh;Byung-Seok Kim;Chang-Yuil Kang;Yeonseok Chung;Hyungseok Seo
    • IMMUNE NETWORK
    • /
    • 제24권1호
    • /
    • pp.2.1-2.24
    • /
    • 2024
  • Studies over the last 2 decades have identified IL-17 and IL-21 as key cytokines in the modulation of a wide range of immune responses. IL-17 serves as a critical defender against bacterial and fungal pathogens, while maintaining symbiotic relationships with commensal microbiota. However, alterations in its levels can lead to chronic inflammation and autoimmunity. IL-21, on the other hand, bridges the adaptive and innate immune responses, and its imbalance is implicated in autoimmune diseases and cancer, highlighting its important role in both health and disease. Delving into the intricacies of these cytokines not only opens new avenues for understanding the immune system, but also promises innovative advances in the development of therapeutic strategies for numerous diseases. In this review, we will discuss an updated view of the immunobiology and therapeutic potential of IL-17 and IL-21.

마우스에 있어서 Interleukin -2의 투여방법이 Meth-A 종양세포에 대한 항암효과에 미치는 영향 (Effect of Interleukin-2 Administration Route on Antitumor Response Against Subcutaneous Meth-A Tumor in Mice)

  • 권오덕
    • 한국임상수의학회지
    • /
    • 제17권2호
    • /
    • pp.311-315
    • /
    • 2000
  • Recombinant interleukin-2 (IL-2) has been demonstated as an antineoplastic agent in mice and human, and the route of administration is important to IL-2-induced therapeutic responses. Therefore, the current experiment was undertaken to clarify the effect of IL-2 administration route on antitumor response against subcutaneous Meth-A tumor in mice. At the beginning of each experiment, normal BALB/c mice were injected subcutaneously with $5{\times}10^6$ Meth-A tumor cells. Beginning on day 7, experimental groups were treated with a 5-day course of IL-2 (intraperitoneal or subcutaneous injection of 30, 000 IU every 12 hours for 5 days). The result of this experiment revealed that Meth-A tumor grew progressively in control mice. Intraperitoneal IL-2 treatment decreased significantly tumor growth and prolonged survival, compared with control mice. Subcutaneous IL-2 treatment decreased significantly tumor growth until day 11 and tumor cells, grew progressively thereafter, but mice in this group survived longer than control mice.

  • PDF

IgA 신병증 환자에서 Interleukin-17 수용체 A 유전자의 단일염기다형성 연관성 연구 (Association between polymorphisms in Interleukin-17 receptor A gene and childhood IgA nephropathy)

  • 백승아;한원호;조병수;김성도
    • Clinical and Experimental Pediatrics
    • /
    • 제53권2호
    • /
    • pp.215-221
    • /
    • 2010
  • 목 적 : IgA 신병증은 세계적으로 가장 흔한 사구체 질환으로 최근 들어 interleukin (IL)-17의 면역조절 반응에 있어서의 관련성이 밝혀지고 있다. 이 연구에서는 IL-17RA 유전자의 단일 염기다형성과 소아 IgA 신병증의 발생 및 진행과의 연관성을 알아보고자 하였다. 방 법 : 조직 검사를 통해 확인된 IgA 신병증 환아 156명과 건강한 정상 성인 245명을 대조군으로 하여 말초혈액을 채취하였다. PCR 방법으로 IL-17RA 유전자의 SNP (rs2895332, rs1468488, rs4819553)를 분석하였다. 환자군을 단백뇨(${\leq}4$ and >$4mg/m^2/hr$, ${\leq}40$ and >$40mg/m^2/hr$)와 병리학적 진행 여부에 따라서 두 그룹으로 나누어 IL-17RA SNP와의 연관성을 확인하였다. 결 과 : IgA 신병증 환자군과 정상 대조군에서 IL-17RA 유전자 rs2895332, rs1468488, rs4819553의 발현율은 통계적으로 유의한 차이가 없었다. 또한 IL-17RA 유전자 각각에 대하여, 병리학적 진행성 병변을 가진 군과 그렇지 못한 군 사이에 통계학적으로 유의한 차이가 없었다. 그러나 rs2895332 유전자의 경우, 단백뇨가 있는 군(단백뇨>$4mg/m^2/hr$)과 없는 군(단백뇨${\leq}4mg/m^2/hr$)에서는 두 군간에 통계적으로 유의한 차이를 보였다. 결 론 : IL-17RA 유전자 rs2895332의 단일염기다형성은 소아의 IgA 신병증에서 단백뇨의 발생과 통계학적으로 의미 있는 연관성이 있었다.

Suppressive Effects of a Truncated Inhibitor K562 Protein-Derived Peptide on Two Pro-inflammatory Cytokines, IL-17 and TNF-α

  • Hwang, Jong Tae;Yu, Ji Won;Nam, Hee Jin;Song, Sun Kwang;Sung, Woo Yong;Kim, Yongae;Cho, Jang-Hee
    • Journal of Microbiology and Biotechnology
    • /
    • 제30권12호
    • /
    • pp.1810-1818
    • /
    • 2020
  • Inhibitor K562 (IK) protein was first isolated from the culture medium of K562 cells, a leukemia cell line, and is an inhibitory regulator of interferon-γ-induced major histocompatibility complex class II expression. Recently, exogenous truncated IK (tIK) protein showed potential as a therapeutic agent for inflammation-related diseases. In this study, we designed a novel putative anti-inflammatory peptide derived from tIK protein based on homology modeling of the human interleukin-10 (hIL-10) structure, and investigated whether the peptide exerted inhibitory effects against pro-inflammatory cytokines such as IL-17 and tumor necrosis factor-α (TNF-α). The peptide contains key residues involved in binding hIL-10 to the IL-10 receptor, and exerted strong inhibitory effects on IL-17 (43.8%) and TNF-α (50.7%). In addition, we used circular dichroism spectroscopy to confirm that the peptide is usually present in a random coil configuration in aqueous solution. In terms of toxicity, the peptide was found to be biologically safe. The mechanisms by which the short peptide derived from human tIK protein exerts inhibitory effects against IL-17 and TNF-α should be explored further. We also evaluated the feasibility of using this novel peptide in skincare products.